Telomir Pharmaceuticals closed at $0.88 on Nov 4, down 3.85%, within 0.0% of its 52-week closing low. Volume of 235.6K shares was 3.35× its 20-day average (well above normal).
Split-adjusted performance: -27.1% over one month, -34.7% over six months, -41.7% over one year.
Short interest was 770.0K shares at the Oct 15 settlement, down 6.7% from the prior report (2.1% of float, 4.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TELOTelomir Pharmaceuticals | $0.8750 | −3.85% | −34.7% | — | — | — | $64.5M | |
| FBIOFortress Biotech | $1.97 | +1.55% | −22.7% | +14.0% | −13.2% | 0.6 | $65.7M | Compare |
| RANIRani Therapeutics Holdings | $0.5728 | +3.06% | −40.3% | — | −432.7% | — | $66.1M | Compare |
| CINGCingulate | $4.56 | −3.39% | −14.4% | — | — | — | $66.3M | Compare |
| CPIXCumberland Pharmaceuticals | $4.44 | +3.02% | +1.6% | −56.3% | −2569.0% | — | $66.5M | Compare |
| QUCYQuantum Cyber N.V | $0.7430 | +2.65% | — | — | — | — | $62.5M | Compare |
| SPROSpero Therapeutics | $1.07 | +2.88% | −57.7% | −100.0% | — | 8.4 | $62.3M | Compare |
| TENXTenax Therapeutics | $1.81 | −1.63% | −84.9% | — | — | — | $67.7M | Compare |
| GOSSGossamer Bio | $9.95 | +7.22% | −64.5% | −19.6% | 182.9% | — | $60.9M | Compare |
No recent articles focused on Telomir Pharmaceuticals.
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
